Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) that remains unlicensed in the UK, with no MHRA approval, no NHS availability, and no BNF listing as of 20242025
Drucker, who, like Dr
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2017 Executive Summary
It is also important for individuals to have realistic weight loss goals and be committed to making lifestyle changes, such as adopting a healthy diet and engaging in regular physical activity, to achieve long-term weight management success with Semaglutide GLP-1 treatment
Because it is still being trialed, physicians do not have a long-term use scheme for it yet
In a retrospective cohort study of patients with type 2 diabetes, coadministration with serotonergic antidepressants (eg, citalopram/escitalopram) was associated with attenuation of the weight loss effects of GLP-1 agonists